Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide

Journal of Clinical Microbiology

Volumn 50, Issue 2, 2012, Pages 428-434

  Simons, Sami O ^a   Van Ingen, Jakko ^a   Van Der Laan, Tridia ^b   Mulder, Arnout ^b   Dekhuijzen, P N Richard ^a   Boeree, Martin J ^a   Van Soolingen, Dick ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PYRAZINAMIDE;

ACCURACY; ADOLESCENT; ADULT; ALGORITHM; ANALYTICAL EQUIPMENT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM DETECTION; BACTERIUM ISOLATE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ERROR; FALSE POSITIVE RESULT; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; MALE; MICROBIOLOGICAL EXAMINATION; MUTATIONAL ANALYSIS; MYCOBACTERIAL GROWTH INDICATOR TUBE METHOD; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PNCA GENE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENSITIVITY AND SPECIFICITY; TRUE POSITIVE RESULT; VALIDATION STUDY; VARIABLE NUMBER OF TANDEM REPEAT;

ADOLESCENT; ADULT; AGED, 80 AND OVER; AMIDOHYDROLASES; ANTITUBERCULAR AGENTS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 84856146642     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.05435-11     Document Type: Article

References (32)

1. Becton Dickinson and Company. 1999. Bactec MGIT 960 system user's manual. Becton Dickinson and Company, Sparks, MD.
2. Bishop KS, et al. 2001. Characterisation of the pncA gene in Mycobacterium tuberculosis isolates from Gauteng, South Africa. Int. J. Tuberc. Lung Dis. 5:952-957. (Pubitemid 32976641)
3. Chang KC, Yew WW, Zhang Y. 2011. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses. Antimicrob. Agents Chemother. 55:4499-4505.
4. Chedore P, Bertucci L, Wolfe J, Sharma M, Jamieson F. 2010. Potential erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Clin. Microbiol. 48:300-301.
5. Devaux I, Kremer K, Heersma H, van Soolingen D. 2009. Clusters of multidrug-resistant Mycobacterium tuberculosis cases. Europe. Emerg. Infect. Dis. 15:1052-1060.
6. Doustdar F, Khosravi AD, Farnia P. 2009. Mycobacterium tuberculosis genotype diversity in pyrazinamide-resistant isolates of Iran. Microb. Drug Resist. 15:251-256.
7. Hannan MM, Desmond EP, Morlock GP, Mazurek GH, Crawford JT. 2001. Pyrazinamide-monoresistant Mycobacterium tuberculosis in the United States. J. Clin. Microbiol. 39:647-650. (Pubitemid 32150834)
8. Hirano K, Takahashi M, Kazumi Y, Fukasawa Y, Abe C. 1997. Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. Tuber. Lung Dis. 78:117-122. (Pubitemid 28080549)
9. Huang TS, et al. 2003. Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan. Antimicrob. Agents Chemother. 47:3672-3673.
10. Kamerbeek J, et al. 1997. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J. Clin. Microbiol. 35:907-914. (Pubitemid 27146535)
11. Konno K, Feldman FM, McDermott W. 1967. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am. Rev. Respir. Dis. 95:461-469.
12. Lew W, Pai M, Oxlade O, Martin D, Menzies D. 2008. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann. Intern. Med. 149:123-134. (Pubitemid 352008599)
13. McDermott W, Thompson R. 1954. Activation of pyrazinamide and nicotinamide in acidic environment in vitro. Am. Rev. Tuberc. 70:748-754.
14. Morlock GP, et al. 2000. Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 44:2291-2295. (Pubitemid 30650870)
15. Mphahlele M, et al. 2008. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J. Clin. Microbiol. 46:3459-3464.
16. Pandey S, Newton S, Upton A, Roberts S, Drinkovic D. 2009. Characterisation of pncA mutations in clinical Mycobacterium tuberculosis isolates in New Zealand. Pathology 41:582-584.
17. Parwati I, Van Crevel R, Van Soolingen D. 2010. Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. Lancet Infect. Dis. 10:103-111.
18. Piersimoni C, Olivieri A, Benacchio L, Scarparo C. 2006. Current perspectives on drug susceptibility testing of Mycobacterium tuberculosis complex: the automated nonradiometric systems. J. Clin. Microbiol. 44:20-28. (Pubitemid 43100573)
19. Scorpio A, Zhang Y. 1996. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med. 2:662-667. (Pubitemid 26191953)
20. Scorpio A, et al. 1997. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 41:540-543. (Pubitemid 27098400)
21. Shi W, et al. 2011. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 16:1630-1632.
22. Singh P, et al. 2007. Comparative evaluation of Löwenstein-Jensen proportion method, BacT/ALERT 3D system, and enzymatic pyrazinamidase assay for pyrazinamide susceptibility testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 45:76-80. (Pubitemid 46106409)
23. Slump E, Erkens CGM, Kalisvaart NA, Van Rest J, Šebek M, Van Soolingen D. 2010. Tuberculosis in the Netherlands 2009. KNCV Tuberculosis Foundation, the Hague, the Netherlands. (In Dutch.)
24. Springer B, Lucke K, Calligaris-Maibach C, Ritter C, Böttger EC. 2009. Quantitative drug susceptibility testing of Mycobacterium tuberculosis by the use of MGIT 960 and EpiCenter Instrumentation. J. Clin. Microbiol. 47:1773-1780.
25. Supply P, et al. 2006. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J. Clin. Microbiol. 44:4498-4510. (Pubitemid 44937085)
26. van Embden JD, et al. 1993. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J. Clin. Microbiol. 31:406-409.
27. van Klingeren B, Dessens-Kroon M, Van der Laan TT, Kremer K, Van Soolingen D. 2007. Drug susceptibility testing of Mycobacterium tuberculosis complex by use of a high-throughput, reproducible, absolute concentration method. J. Clin. Microbiol. 45:2662-2668. (Pubitemid 47295501)
28. World Health Organization. 2010. Treatment of tuberculosis: guidelines, 4th ed. WHO, Geneva, Switzerland.
29. Wright, A. 2009. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance. Surveillance 373:1861-1873.
30. Yeager RL, Munroe WGC, Dessau FI. 1952. Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis. Am. Rev. Tuberc. 65:523-546.
31. Zhang Y, Mitchison D. 2003. The curious characteristics of pyrazinamide: a review. Int. J. Tuberc. Lung Dis. 7:6-21. (Pubitemid 36427026)
32. Zhang Y, Wade MM, Scorpio A, Zhang H, Sun Z. 2003. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetic by pyrazinoic acid. J. Antimicrob. Chemother. 52:790-795. (Pubitemid 37407806)